Table 2.
Safety of S-1, number of subjects (%)
Neoadjuvant chemotherapy with S-1 (N = 106) | |
---|---|
Patients with any AE | 78 (74) |
AE leading to death | 0 (0) |
Any SAE | 1 (1) |
AE leading to discontinuation of S-1 | 20 (19) |
White blood cell decrease | 30 (28) |
Anemia | 27 (25) |
Thrombocytopenia | 26 (25) |
Bilirubin increase | 19 (18) |
Pruritus | 8 (8) |
ALT increase | 9 (8) |
AE, adverse event; SAE, serious adverse event.